Aclaris Therapeutics ACRS Other comprehensive income (loss)
Other comprehensive income (loss) at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTax.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's other comprehensive income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's other comprehensive income (loss)?
- Aclaris Therapeutics (ACRS) reported other comprehensive income (loss) of -$588K in Q1 2026.
- How has Aclaris Therapeutics's other comprehensive income (loss) changed year-over-year?
- Aclaris Therapeutics's other comprehensive income (loss) decreased by 274.5% year-over-year, from $337K to -$588K.
- What is the long-term trend for Aclaris Therapeutics's other comprehensive income (loss)?
- Over 2 years (2021 to 2025), Aclaris Therapeutics's other comprehensive income (loss) has grown at a 98.6% compound annual growth rate (CAGR), from -$130K to $513K.
- What does other comprehensive income (loss) mean?
- Includes all changes in equity during a period resulting from transactions and other events, excluding those resulting from investments by owners and distributions to owners. This metric encompasses items like unrealized gains or losses on securities that are not included in net income. It provides a broader view of the company's total financial performance and changes in net worth beyond standard operating results.